Navigation Links
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Date:10/25/2008

ss.

About the AMBITION Study

AMBITION (Actemra versus Methotrexate double-Blind Investigative Trial In mONotherapy), a two-arm, randomized, double-blind, placebo-controlled study, was designed to evaluate the non-inferiority and subsequent superiority of ACTEMRA monotherapy in patients with RA compared with methotrexate alone at 24 weeks. Patients who had not received methotrexate for at least six months beforehand were randomized to receive either ACTEMRA (8 mg/kg) intravenously every four weeks plus placebo capsules weekly or placebo infusions every four weeks plus methotrexate weekly. The study evaluated 673 patients from 252 sites in 18 countries, including the United States.

In the AMBITION study, 70 percent, 44 percent and 28 percent of patients in the ACTEMRA (8 mg/kg) arm achieved ACR20, ACR50 and ACR70, respectively, compared with 53 percent, 34 percent and 15 percent, respectively, of patients treated with methotrexate alone. Disease remission (DAS28 <2.6) was demonstrated in 34 percent of ACTEMRA patients compared with 12 percent of patients in the control group. A higher proportion of ACTEMRA (8 mg/kg) patients achieved a significant EULAR response(3) as early as the second week in the study. Levels of C-reactive protein (CRP), a marker of inflammation, and hemoglobin levels showed rapid normalization in as early as two weeks in ACTEMRA (8 mg/kg) patients in the AMBITION study, compared with patients treated with methotrexate alone.

ACTEMRA was generally well tolerated and the adverse event rates were similar in the group treated with ACTEMRA compared with patients treated with methotrexate alone (80 percent and 78 percent, respectively).

In both studies, patients treated with ACTEMRA alone or with methotrexate achieved greater improvements in quality-of-life measures, including fatigue, pain, and physical and mental functions, compared with methotrexate.

About ACTEMRA(R) (tocilizumab)

ACTEMRA is the fir
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
4. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... SANTA CLARA, Calif. , May 21, ... a game-changing embedded-ultrasound platform, today announced the ... Toolkit that allows complete network-based communications with ... demonstrate its latest embedded-ultrasound technology, including this ... Sao Paulo, Brazil ...
(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ... and microfluidic cell-based assay platforms, today announced the appointment ... DABT to the Company,s Board of Directors. Dr. MacDonald ... of the Schering-Plough Research Institute ("SPRI"), which was the ... acquisition by Merck & Co. in 2009. ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:5/21/2013)... (PRWEB) May 21, 2013 Diversity Focus, ... working environments for all residents in the Creative Corridor ... Community Survey at a news conference on Thursday, May ... benchmark study, conducted in 2008. , The ... to lead and support efforts that attract, nurture and ...
(Date:5/21/2013)... 2013 Modern couples have countless ... Texas Counseling’s Sexuality and Relationship Workshops, couples are ... of healthier habits for their relationship. There are ... couples and individuals at Texas Counseling. Their goal ... learn skills to develop long term solutions. ...
(Date:5/21/2013)... 21, 2013) Research into genetic features of pulmonary ... Colorado School of Medicine may lead to improved treatment ... published online by JAMA . , The study ... in some cases of pulmonary fibrosis, a chronic progressive ... a result of the study, researchers may want to ...
(Date:5/21/2013)... Adenotonsillectomy, or the removal of the adenoids and tonsils, ... States, often as a treatment for children with obstructive ... a child,s attention and executive functioning, behavior, sleep apnea ... evaluated until now. A study led by Susan ... Sleep and Cardiovascular Medicine and Associate Clinic Director of ...
(Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3
... guinea worm disease is almost eradicated from the planet earth. ... could be exterminated in a couple of years from now. ... ,Currently around 25,000 people in nine countries across the ... million people in twenty countries in the early 1980s. ...
... performance is reported to be the latest trend which is ... keen to learn and develop their skills to make sure ... interest of patients. ,More than 170 physician ... emergency care through the Physician Consortium for Performance Improvement organized ...
... cancers of the “triple negative” type are destructive and lethal, ... to a novel// study Published in the May 1, 2007 ... these tumors occur commonly among women who are African American ... the lower socioeconomic status (SES). The study also showed that ...
... children suffering ADHD are prone to alcohol addiction in ... suggesting that alcohol related problems could begin around the ... family stress appear to add to the risk of ... that children with attention deficit hyperactivity disorder (ADHD) are ...
... the incidence of chicken pox cases is on the rise. ... especially in the southern districts, are gearing up to tackle ... would be the first casualty if chicken pox is not ... cases have been already reported in a rather serious condition ...
... Going in for angioplasty? Pause for a moment. It has now ... arteries//. ,So much so, more than half a ... or premature angioplasty, suggests a new study. ,More important, ... heart patients, it says. ,Dr William Boden of ...
Cached Medicine News:Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 2Health News:ADHD Problem in Children – a Risk Factor for Alcohol Problems in Later Lif 3
ABS2000 is an automated system that can handle more workload. It allows accurate detection of antibodies that can be missed out by manual testing....
The ScanGel® automatic readings are done with a high resolution color video camera. Images can be stored and printed....
... System for endovenous occlusion of varicose ... with a family of disposable catheters to ... energy. With VNUS ClosurePlus , ... catheters, physicians can treat incompetent saphenous, ...
Thesystem combines an exclusive dual light-source design and a versatile sample compartment to provide solid, reliable performance....
Medicine Products: